OptimizeRx Corporation reports developments in healthcare technology for life sciences marketing, with updates centered on tools that connect pharmaceutical brands with healthcare professionals and patients. The company’s platform uses EHR-based access, omnichannel activation, the Dynamic Audience Activation Platform, and Micro-Neighborhood audiences to support HCP and direct-to-consumer engagement.
Recurring OptimizeRx news includes product and network launches, programmatic access to EHR advertising, privacy-safe identity resolution collaborations, quarterly and annual results, debt and share-repurchase actions, and board or leadership changes. Coverage also reflects the company’s focus on privacy-compliant audience targeting and campaign measurement across healthcare marketing channels.
OptimizeRx Corp (Nasdaq: OPRX) has successfully integrated its TelaRep solution into its Therapy Initiation and Persistence Platform, enhancing connectivity for healthcare providers (HCPs). Launched in April 2020, TelaRep facilitates direct communication between HCPs and pharmaceutical representatives, now serving over 200,000 in-network providers. The solution’s effectiveness is exemplified by a 37% increase in prescriptions in specific territories. This development addresses the ongoing challenges faced by pharmaceutical sales forces and highlights the growing importance of digital communication in healthcare.
OptimizeRx Corp (Nasdaq: OPRX) announced its participation in three major conferences, including the 42nd Annual William Blair Growth Stock Conference in Chicago from June 6-9, the Stifel 2022 Cross Sector Conference in Boston from June 7-9, and the Roth Capital Partners 8th Annual London Conference from June 21-23. Each event will feature opportunities for management to present and hold one-on-one meetings with investors. OptimizeRx provides critical point-of-care technology solutions to enhance patient therapy adherence.
OptimizeRx Corp (Nasdaq: OPRX) announced that Mike Rousselle, its vice president of data product, has been named one of the 2022 PM360 ELITE 100 in the Data Miners category. Rousselle is recognized for his work in applying AI and ML in healthcare marketing, streamlining engagement with healthcare providers at the point-of-care. Steve Silvestro, CCO, highlighted Rousselle's role in driving innovation and efficiency in data solutions for life sciences clients. The PM360 ELITE Awards celebrate influential figures in healthcare, with 100 winners selected from over 500 nominations.
OptimizeRx Corp (Nasdaq: OPRX) has announced a share repurchase program authorized by its Board of Directors, allowing the company to buy back up to $20 million of its outstanding common stock. CEO Will Febbo indicated this decision reflects the company's commitment to disciplined capital allocation aimed at enhancing shareholder returns. The repurchase aims to strengthen shareholder value while ensuring sufficient working capital for future growth initiatives, including organic growth and potential M&A activities.
OptimizeRx (Nasdaq: OPRX) announced its participation in the RBC Healthcare Conference on May 17-18, 2022, and the B. Riley Annual Institutional Conference on May 25-26, 2022. The company will partake in a fireside chat at the RBC event on May 18 at 2:05 PM ET, and present at the B. Riley conference on May 26 at 9:30 AM PT. Management will also hold one-on-one meetings at both events. OptimizeRx is a leading provider of point-of-care technology that connects patients and healthcare providers to improve medication adherence.
OptimizeRx Corp. (Nasdaq: OPRX) reported Q1 2022 revenue of $13.7 million, a 22% increase YoY. Gross profit rose 32% to $8.1 million, with gross margins at 59%. Net loss was $3.8 million or $(0.21) per share. The company completed the acquisition of EvinceMed and maintains a strong cash position of $89.0 million. OPRX reaffirms its 2022 revenue outlook of $80 million to $85 million, targeting 31% to 39% growth. The firm is experiencing positive cash flow from operations with a focus on growth through expanding client engagement.
Summary not available.
OptimizeRx Corp (Nasdaq: OPRX) announces a conference call on May 4, 2022, at 4:30 p.m. Eastern Time to discuss its first-quarter financial results for the period ending March 31, 2022. A press release with the financial results will precede the call. Participants can join by telephone or webcast, with a replay available for 12 months on the company’s website. OptimizeRx provides point-of-care technology solutions, connecting healthcare providers and patients to enhance medication adherence.
Summary not available.
Summary not available.